New Pharmaceutical Industry Report Sheds Light on Authorship Selection, Transitions in Scientific Publications Process

Saturday, April 14, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

CHAPEL HILL, N.C., April 13, 2018 /PRNewswire/ -- It's hard to overemphasize the importance of scientific publications to

the pharmaceutical industry - it is the principal way that physicians and KOLs learn scientific/medical information about a company's existing and pipeline products.

But the publications process can get bogged down by gray areas such as authorship

selection. Likewise, many companies aren't sure how to handle author transitions to another company or institution. To provide current insights around these time-consuming and important issues, Best Practices, LLC undertook benchmarking research to examine the industry's current approach to authorship selection.

This new research study reviews the standards, processes and rationale of critical authorship selection and retention decisions. Publications leaders can use this research to shape their publication policies to avoid uncertainties and delays. Specifically, this study provides insights on guidance on the removal of an author from the publication, when an author is leaving for a competitor/non-competitor, circumstances under which former employee is allowed to remain lead author, and specification of authorship rights in employment contract.

In the study, a majority of companies said they don't balance the ratio of internal to external authors since ICMJE criteria don't differentiate between them. The study also found that there is no agreement on who is the best arbiter for determining who will be invited to be an author, although some type of group (publication team or trial-steering committee) is used by 48%.

"Authorship Selection for Medical Publications at Pharmaceutical and Biotech Companies" will serve as a reference for medical publication leaders to shape their authorship transition guidelines.

Key topics in the 48-page study include:

  • Criteria and Process for Different Types of Publications
  • Defining, Tracking, and Recording Author Contributions
  • Process for Internal vs. External Authors
  • Guidance for Transitioning Authors
  • Joining a Competitor vs Non-competitor
  • Guidance for Transitioning KOLs

For this study, Best Practices, LLC engaged 23 leaders from biopharmaceutical companies and a publication services consultancy in this benchmarking research. The study has two data segments: Large Companies and Small to Medium Companies.

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1492.htm.

For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/. 

ABOUT BEST PRACTICES, LLCBest Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

Cision View original content:http://www.prnewswire.com/news-releases/new-pharmaceutical-industry-report-sheds-light-on-authorship-selection-transitions-in-scientific-publications-process-300629809.html

SOURCE Best Practices, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store